Atrium Therapeutics, Inc. - Common Stock (RNA)

CUSIP: 05370A108

Q4 2021 13F Holders as of 31 Dec 2021

Type / Class
Equity / Common Stock
Shares outstanding
150,858,761
Total 13F shares
45,418,262
Share change
+216,512
Total reported value
$1,079,557,657
Price per share
$23.77
Number of holders
104
Value change
+$3,680,968
Number of buys
47
Number of sells
42

Quarterly Holders Quick Answers

What is CUSIP 05370A108?
CUSIP 05370A108 identifies RNA - Atrium Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Atrium Therapeutics, Inc. - Common Stock (RNA) as of Q4 2021

As of 31 Dec 2021, Atrium Therapeutics, Inc. - Common Stock (RNA) was held by 104 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 45,418,262 shares. The largest 10 holders included PRICE T ROWE ASSOCIATES INC /MD/, RTW INVESTMENTS, LP, FMR LLC, BlackRock Inc., EcoR1 Capital, LLC, FEDERATED HERMES, INC., Cormorant Asset Management, LP, VANGUARD GROUP INC, Avidity Partners Management LP, and STATE STREET CORP. This page lists 104 institutional shareholders reporting positions in this security for the Q4 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.